

HCG and Cvergenx Partner to Launch Genomic Radiation Therapy *Strategic initiative in precision radiation therapy to transform radiation therapy and cancer care in India and Africa.*

Bengaluru, India and Tampa, Florida, December 21, 2017. Healthcare Global Enterprises, Ltd. (HCG:NSE) and Cvergenx, Inc. today announced an exclusive collaboration to develop, validate and launch precision genomic radiation therapy (pGRT™) technology in India and Africa. HCG and Cvergenx shall form a joint venture which shall be the exclusive vehicle through which this technology will be made available in those countries.

The proprietary pGRT™ platform, developed at Cvergenx by Dr. Javier Torres-Roca, co-founder and Director, Clinical Research, Department of Radiation Oncology, Moffitt Cancer Center & Research Institute, is the first clinically validated approach to guide radiation dosage based upon the Radiosensitivity Index (RSI) of patients. The HCG/Cvergenx joint venture shall be the first initiative to validate and bring into clinical practice a solution that integrates genomics into radiation treatment planning and therapy in India.

“We are excited to be the first to bring precision genomics based radiation therapy to India. This pioneering technology will allow oncologists to precisely decide radiation treatment for cancer patients based on their genomic profile. It has the potential to truly revolutionize cancer care” said **Dr. B.S. Ajaikumar, Chairman and CEO of HCG.**

“HCG is redefining cancer care across India and Africa through its network of comprehensive cancer centers” said **Raymond F. Vennare, CEO of Cvergenx.** “Their steadfast commitment to seeking out and adopting the latest advancements in technology aligns precisely with our own desire to bring radiation oncology into the era of personalized medicine. The ability to partner with HCG represents a significant move forward for Cvergenx and the practice of radiation therapy”.

About HCG Enterprises Ltd.:

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru is the largest provider of cancer care in India. Through its network of 20 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG’s comprehensive cancer centers provide expertise and advanced technologies required for the effective diagnosis and treatment of cancer under one roof. HCG has pioneered the introduction and adoption of several technologies in the country including stereotactic radiosurgery, robotic radiosurgery and the use of genomics for personalized treatment of cancer. **For further information, visit www.hcgel.com or contact: Company Secretary and Compliance Officer: Sunu Manuel, investors@hcgoncology.com**

About Cvergenx, Inc.:

Cvergenx, Inc. is a genomic informatics company providing decision-support to radiation oncologists to assist in radiation treatment planning. The Company has developed the first clinically actionable biological measure to enable precision genomic radiation therapy (pGRT™). This critical advance — combining the novel Radiosensitivity Index (RSI) and Genomic Adjusted Dose (GARD) — represents the first approach to genomic radiation therapy for the treatment of cancer. For further information, visit www.cvergenx.com or **contact: Raymond.Vennare@cvergenx.com.**